文献类型：期刊文献

英文题名：Sensitive Detection of Exosomal Biomarkers via a Drop-Shaped Porous Microfluidic Chip for Potential Diagnosis of Alzheimer's Disease

作者：Xu, Huiying[1];Zhang, Yujing[1];Shen, Lihua[1];Yu, Shu[2];Li, Changqing[3];Zeng, Xianfei[4,5];Liu, Qin[1];Ye, Bang-Ce[1]

机构：[1]East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China;[2]Peoples Hosp Chongqing Hechuan, Dept Lab Med, Chongqing City 401320, Peoples R China;[3]Chengdu Eighth Peoples Hosp, Chengdu Med Coll, Dept Lab Med, Geriatr Hosp, Chengdu 610000, Peoples R China;[4]Yanan Univ, Dept Lab Med, Xian Daxing Hosp, Xian 710000, Peoples R China;[5]Northwest Univ, Sch Med, Xian 710069, Peoples R China

年份：2025

卷号：97

期号：28

起止页码：15282

外文期刊名：ANALYTICAL CHEMISTRY

收录：;EI(收录号：20252818758280);WOS:【SCI-EXPANDED(收录号:WOS:001527393600001)】；

基金：This study was supported by grants from the National Natural Science Foundation of China (22374048, 22134003), the National Key Research and Development Program of China (2020YFA0908800), and Natural Science Foundation of Shanghai (22ZR1417800).

语种：英文

外文关键词：Biomarkers - Body fluids - Diagnosis - Fluidic devices - Microfluidics - Neurodegenerative diseases - Noninvasive medical procedures - Proteins

摘要：Alzheimer's disease (AD), a progressive and irreversible neurodegenerative disorder, underscores the critical need for developing noninvasive early diagnostic methods. In recent years, blood-exosome-based diagnostics have emerged as a promising approach, as exosomes carry disease-specific biomarkers. However, sensitive detection of AD biomarkers in serum exosomes remains technically challenging due to the low abundance of target molecules and the complexity of biological samples. To address this limitation, we developed an integrated platform combining a novel drop-shaped porous microfluidic chip for exosome enrichment with a rolling circle amplification (RCA)-based immunomagnetic bead detection system. The microfluidic chip, designed with a unique architecture and enriched with abundant binding sites, enables the selective capture and enrichment of exosomes from complex serum samples, significantly improving the recovery rate and purity of exosomes. Meanwhile, the RCA-based detection system allows precise quantification of exosomal proteins (A beta 42 and p-Tau181), converting biomarker levels into measurable fluorescence signals. This strategy achieves highly sensitive and specific detection of AD biomarkers, facilitating the effective differentiation of AD patients. Our platform offers a noninvasive, scalable solution for early AD diagnosis, holding significant potential for clinical applications and timely intervention.